The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry: Catheterization and Cardiovascular Interventions

D. Bandyopadhyay, S. Sartori, U. Baber, D. Cao, R. Chandiramani, D. Tchétché, A.S. Petronio, J. Mehilli, T. Lefèvre, P. Presbitero, P. Capranzaro, G. Sardella, N.M. Van Mieghem, J. Chandrasekhar, N. Dumonteil, C. Fraccaro, D. Trabattoni, G.W. Mikhail, C. Naber, A. KiniM.-C. Morice, B.E. Claessen, A. Chieffo, R. Mehran

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The prevalence of both chronic kidney disease (CKD) and aortic stenosis (AS) increase with age. Although baseline CKD is frequent in patients undergoing transcatheter aortic valve replacement (TAVR), its significance among women is largely unknown. Methods: Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) is a multinational, prospective registry of women undergoing TAVR for severe AS. We included patients with available baseline estimated glomerular filtration rate (eGFR) and completed 1-year follow-up. Patients were categorized into three groups based on their eGFR: No CKD (normal kidney function to stage 2 CKD: eGFR ≥60 ml/min/1.73 m2); (b) mild CKD (stage 3a CKD: eGFR = 45–59 ml/min/1.73 m2); and (c) moderate/severe CKD (stage ≥3b CKD: eGFR <45 ml/min/1.73 m2). All events were adjudicated according to the Valve Academic Research Consortium (VARC)-2 criteria. Result: Out of 852 women undergoing TAVR, 326 (38.3%) had no CKD, 225 (26.4%) had mild CKD, and 301 (35.3%) had moderate/severe CKD. Women with higher stage of CKD at baseline were more likely to have a history of hypertension, diabetes, atrial fibrillation, anemia, chronic lung disease, hemodialysis, prior percutaneous coronary intervention, and pacemaker implantation. After multivariate adjustment, moderate/severe CKD was associated with a greater risk of 1-year VARC-2 safety endpoints [hazard ratio (HR) 1.68, 95% confidence interval (CI): 1.10–2.60], all-cause death (HR 2.00, 95% CI: 1.03–3.90), and composite of death, myocardial infarction, stroke or life-threatening bleeding (HR 1.70, 95% CI: 1.04–2.76). There were no differences in 30-day and 1-year VARC-2 efficacy and 30-day VARC-2 safety outcomes. Conclusion: CKD is associated with substantial and independent risk for mortality and morbidity at 1-year follow-up in women undergoing TAVR. © 2020 Wiley Periodicals, Inc.
Original languageEnglish
Pages (from-to)198-207
Number of pages10
JournalCatheter. Cardiovasc. Interventions
Volume96
Issue number1
DOIs
Publication statusPublished - 2020

Keywords

  • aortic stenosis
  • chronic kidney disease
  • transcatheter aortic valve replacement
  • WIN-TAVI registry
  • aged
  • all cause mortality
  • anemia
  • anticoagulant therapy
  • Article
  • atrial fibrillation
  • bleeding
  • cardiovascular mortality
  • cerebrovascular accident
  • chronic kidney failure
  • chronic lung disease
  • clinical outcome
  • controlled study
  • diabetes mellitus
  • disease registry
  • disease severity
  • estimated glomerular filtration rate
  • EuroSCORE
  • female
  • follow up
  • hazard ratio
  • heart infarction
  • hemodialysis
  • high risk population
  • human
  • hypertension
  • intensive care unit
  • kidney function
  • length of stay
  • medical history
  • mortality risk
  • observational study
  • pacemaker implantation
  • percutaneous coronary intervention
  • peroperative complication
  • prevalence
  • transcatheter aortic valve implantation
  • very elderly

Fingerprint Dive into the research topics of 'The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry: Catheterization and Cardiovascular Interventions'. Together they form a unique fingerprint.

Cite this